Speaker Profile
PMWC PIONEER AWARD
M.D., Senior investigator, Sinai Health System
Biography
Dr. Daniel Drucker's lab is internationally renowned not only for his research, but as an environment where the clinical relevance of scientific breakthroughs is pursued. In his lab, Dr. Drucker studies the action of peptide hormones that regulate multiple aspects of metabolism. His lab has carried out basic science supporting the development of two new classes of therapies for the treatment of type 2 diabetes, new medicines for obesity and a new therapy for patients with short bowel syndrome requiring parenteral nutrition.
Dr. Drucker studies a family of hormones produced in the pancreas, gastrointestinal tract and brain. Controlling blood glucose and insulin secretion, these hormones also regulate our appetite, the absorption of nutrients from the food we eat, and the conversion of those nutrients to energy. GLP-1 medicines also reduce inflammation, and decreases rates of cardiovascular, kidney and liver disease, improving outcomes for millions of people worldwide.
Talk
The expanding universe of GLP- medicines
Modern GLP-1 medicines improve multiple health outcomes, often independent of weight loss. This lecture highlights the mechanisms of GLP-1 action that reverse organ dysfunction and reduce the complications of cardiometabolic disease
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Michael Goldman, SFSU
PMWC Award Ceremony
• David Sinclair, Harvard
• Steve Horvath, Altos Labs
• Nir Barzilai, Albert Einstein College of Medicine
AI-Driven Biomarkers to Quantify Aging
• Chair: Alex Zhavoronkov, Insilico Medicine
• Mahdi Moqri, Harvard
• Steve Horvath, Altos Labs
• Hussain Ahamed, Ultrahuman
Epigenetic Aging Signatures in Large Human Cohorts
• Varun Dwaraka, TruDiagnostic
AI Systems for Personalized Longevity: How Biomarkers Translate into Actionable Interventions
• Chair: Nathan Price, Buck Institute
• Sherry Zhang, Buck Institute
• Ranjan Sinha, Digbi Health
• Zeenia Framroze, Alethios, Inc.
• John Ramunas, Rejuvenation Technologies
Clinical Trial Design & Functional Endpoints for Healthspan
• Nir Barzilai, Albert Einstein College of Mediciney
The data We Need For AI To Accelerate Longevity Drugs
• Martin Jensen, Gordian Biotechnology
From Genome to an AI-Drive Longevity Platform
• Wei-Wu He, Human Longevity
Wellness Wearables: The Journey to Clinical
• Hussain Ahamed, Ultrahuman
Longevity Medicine: Ambition vs Evidence in the Era of Precision Health
• Aubrey de Grey, LEV Foundation
Precision Aging & Longevity Focused on Limited Lifespan Evidence, Vanishing Blue Zones, and Payer ROI
• S. Jay Olshansky, University of Illinois
Evolutionary perspectives on human lifespan and healthspan
• Michael Gurven, UC Santa Barbara
